◎ Ua paʻi mua ʻia kēia ʻatikala ma ka ʻōlelo Haina kuʻuna ma ka Helu 96 o “Ganoderma” (Kekemapa 2022), a ua paʻi mua ʻia ma ka ʻōlelo Haina maʻalahi ma “ganodermanews.com” (Ianuali 2023), a ua hoʻopuka hou ʻia ma ʻaneʻi me ka ʻae o ka mea kākau.

Ma ka ʻatikala "Ke kumu oReishie pale i ka influenza ─ ʻO ka lawa o ka qi olakino i loko o ke kino e pale i ka hoʻouka ʻana o nā kumu pathogenic" ma ka pukana 46th o "Ganoderma” i ka makahiki 2009, ua haʻi au i ka manaʻo o ka lāʻau lapaʻau kuʻuna Kina e manaʻoʻiʻo ʻo ke olakino a me ka maʻi no nā mokuʻāina like ʻole o ka "paʻakikī ma waena o ke olakino a me ka pathogenic qi".Ma waena o lākou, ʻo ka "qi olakino" e pili ana i ka hiki o ke kino o ke kanaka ke pale aku i nā maʻi, a ʻo ka "qi pathogenic" e pili ana i nā maʻi maʻi a me nā maʻi bacteria e hoʻopilikia i ke kino kanaka a i ʻole nā ​​​​maʻi koko e hoʻopuka i loko o ke kino.

ʻO ia hoʻi, aia ke kanaka i ke kūlana olakino no ka mea lawa ka qi olakino i loko o ke kino e pale i ka hoʻouka ʻana o nā kumu pathogenic, ʻo ia hoʻi, he ikaika ko ke kino o ke kanaka e pale aku i nā maʻi, ʻaʻole ia he manaʻo ʻaʻohe pathogenic qi i loko o ke kino akā ʻo ia hoʻi, ʻaʻole hiki i ka pathogenic qi i ke kino ke hoʻopau i ka qi olakino;ke kanaka i loko o ka maʻi no ka mea pathogenic kumu hoʻokomo i ke kino hemahema i ka qi olakino, ʻo ia hoʻi, ka hemahema o ka qi olakino e hoʻonāwaliwali i ke kino o ka maʻi kū'ē, a me ka hōʻiliʻili o nā kumu pathogenic i loko o ke kino alakai i ka maʻi.ʻO ke ala kūpono o ka mālama ʻana ʻo ka hoʻopau loa ʻana i nā kumu pathogenic.Eia nō naʻe, a hiki i kēia manawa, ʻaʻole hiki i nā lāʻau lapaʻau Komohana a me nā lāʻau lapaʻau Kina ke hoʻopau loa i kekahi mau kumu pathogenic.

ʻAʻole anei ʻo ia ka hihia me ka maʻi coronavirus hou o kēia lā?Ma muli o ka nele o nā lāʻau antiviral kūikawā, ʻaʻole hiki i ka lāʻau komohana a i ʻole ka lāʻau lapaʻau Kina kuʻuna ke pepehi pono i nā maʻi.ʻO ke kumu e ola hou ai ka poʻe i maʻi ʻia, ʻo ia ka hilinaʻi ʻana i ka hoʻoikaika ʻana i ke kino o ke kino (healthy qi) ma ke kumu o ka mālama ʻana i nā hōʻailona (hoʻomaha i nā hōʻailona hōʻoluʻolu) e hoʻomaʻemaʻe i ka maʻi (pathogenic qi).

ʻO ka ʻōnaehana pale kino ikaika ka mea paʻakikī i nā maʻi maʻi ke hoʻoulu i ka maʻi. 

ʻO ka novel coronavirus (SARS-CoV-2) ua hoʻopilikia a luku i ka honua no 3 mau makahiki.I ka hopena o 2022, ua ʻoi aku ma mua o 600 miliona mau kānaka i ka maʻi a ʻoi aku ma mua o 6 miliona mau kānaka i make.I kēia manawa, ke hoʻolaha nui nei nā ʻano Omicron o ka novel coronavirus a puni ka honua.ʻOiai ua hoʻemi ʻia ko lākou pathogenicity a me ka nui o ka make, he maʻi lele loa ia a he kiʻekiʻe loa kona maʻi.

ʻAʻole hiki i nā lāʻau antiviral i kēia manawa ke pepehi i nā maʻi maʻi kūikawā, akā hiki ke pale wale i ka hoʻonui ʻana o nā maʻi.Ma waho aʻe o nā hana pale maʻamau e like me ke kāʻei ʻana i nā masks, ka mālama ʻana i ka hoʻomaʻemaʻe lima, ka mālama ʻana i ka hele ʻana o ka nohona, a me ka pale ʻana i nā hōʻuluʻulu ʻana, ʻo ka mea nui loa ʻaʻole ia he "hoʻoikaika kino qi".

ʻO ka Immunity e pili ana i ka hiki i ke kino o ke kino ke pale a hoʻopau i ka hoʻouka ʻana o nā pathogens e like me ka bacteria a me nā maʻi virus, e wehe i ka ʻelemakule, nā mea make a i ʻole nā ​​​​mea hoʻololi i loko o ke kino a me nā mea e hoʻoulu ai i ka maʻi maʻi, mālama i ka paʻa o ke kaiapuni i loko o ke kino a mālama i ke kino.

ʻO nā kumu he nui e like me ke koʻikoʻi o ka noʻonoʻo, ka hopohopo, ka hana nui, ka ʻai ʻole, ka maʻi hiamoe, ka hoʻomaʻamaʻa ʻole, ka ʻelemakule, nā maʻi a me nā lāʻau lapaʻau hiki ke hoʻopilikia i ke kino o ke kino a hiki ke hoʻoulu i ka hypofunction immune a i ʻole ka pale ʻana.

I ka wā o ka maʻi ahulau, ʻaʻole i maʻi kekahi poʻe i pili kokoke i ka poʻe i loaʻa i ka novel coronavirus a lilo i mau hihia asymptomatic;ua maʻi kekahi poʻe akā loaʻa nā hōʻailona maʻalahi.

ʻO ke kumu o kēia poʻe asymptomatic a i ʻole nā ​​​​hōʻailona maʻalahi ʻo ia ka pale ʻana o ke kino (healthy qi) i ka maʻi (pathogenic qi).Ke lawa ka qi olakino i ke kino, ʻaʻohe ala e komo ai nā kumu pathogenic i ke kino.

ʻO ke kiʻikuhi Schematic o Reishi e hoʻoikaika ana i ka qi olakino a me ka hoʻopau ʻana i nā pathogens

Reishihoʻonui i ka palekana a pale i nā maʻi viral.

Reishihe hopena hoʻoikaika kino.ʻO ka mea mua, hiki iā Reishi ke hoʻoikaika i ka hana kino ʻole o ke kino, me ka hoʻoulu ʻana i ka maturation, ka ʻokoʻa a me ka hana o nā cell dendritic, hoʻonui i ka hana pepehi ʻana o nā macrophages mononuclear a me nā mea pepehi maoli, a hiki ke hoʻopau pololei i nā maʻi maʻi.

ʻO ka lua,Reishihoʻonui i nā hana o ka palekana humoral a me ka palekana cellular e like me ka paipai ʻana i ka hoʻonui ʻana o nā cell B, ka hoʻoikaika ʻana i ka hana ʻana o ka immunoglobulin (antibody) IgM a me IgG, e hoʻoikaika ana i ka hoʻonui ʻana o nā cell T, hoʻonui i ka hana pepehi ʻana o nā cell cytotoxic T (CTL), a hoʻolaha i ka hana ʻana o nā cytokines e like me interleukin-1 (IL-1), interleukin-2 (IL-2) a me interferon-gamma (IFN-gamma).

Ua hōʻike ʻia nā haʻawina e hiki iā Reishi ke kāohi i ka pakele ʻana o nā cell tumor, akā inā he hopena like ia i ka pakele ʻana o nā maʻi maʻi e hoʻomau ʻia e aʻo hou ʻia.Eia nō naʻe, no ka hypofunction immune i hoʻokumu ʻia e nā kumu like ʻole e like me ke kaumaha noʻonoʻo, hopohopo, hana nui, ʻelemakule, maʻi a me nā lāʻau lapaʻau,Reishiua hōʻoia ʻia e kōkua i ka hoʻihoʻi ʻana i ka hana maʻamau.

Hāʻawi ka hopena immune-boosting o Reishi i kumu kumu no ka pale ʻana i ka maʻi coronavirus.

Reishihoʻomaha i kaʻuhane, pale i ka pilikia a hoʻonui i ka palekana.

I ka wā o ka maʻi maʻi COVID-19, ua ʻike kekahi poʻe i ka makaʻu, ka haʻalulu, ka hopohopo, nā maʻi hiamoe, a me ke kaumaha ma muli o ke koʻikoʻi noʻonoʻo i hoʻokumu ʻia e ka maʻi COVID-19 a i ʻole ka pale ʻana i ka maʻi maʻi a me nā hana hoʻomalu, e pili ana ia mau mea āpau i ka pale ʻana.

Ma ka ʻatikala "Nā Hoʻāʻo holoholona a me nā hoʻokolohua kanaka oGanoderma LucidumAgainst Stress-Induced Immune Function Suppression” ma ka pukana 63 oGanodermai ka makahiki 2014, ua kamaʻilio wau e pili ana i nā hoʻokolohua lāʻau lapaʻauʻO Ganoderma lucidumhoʻomaikaʻi i ka hana ʻana o nā ʻiole ma muli o ke kaumaha.Hōʻike kēia pepa e hiki i ke koʻikoʻi kino a me ka noʻonoʻo i hana ʻia e ka hoʻomaʻamaʻa kiʻekiʻe e hiki ke hoʻopau i ka hana immune o nā mea pāʻani, akā hiki i ka Ganoderma lucidum ke hoʻomaikaʻi i ka hana immune.

Pili kēia mau hopena i nā hiʻohiʻona hoʻoikaika kino a me ka hoʻomaha ʻuhane oReishi.I kekahi huaʻōlelo, kōkua ʻo Reishi i ka hoʻohaʻahaʻa ʻana i ke kaumaha noʻonoʻo ma o kāna mau hopena e like me ka sedative hypnosis, anti-anxiety, a me ka anti-depression.No laila, ʻaʻole paʻakikī ke noʻonoʻo i ka hiki ke hoʻohaʻahaʻa i ka ʻuhane o Reishi i ke kaumaha o ka noʻonoʻo i hoʻokumu ʻia e ka maʻi maʻi COVID-19 a hoʻonui i ka pale.

ʻO Ganoderma lucidumloaʻa pū kekahi hopena anti-novel coronavirus.

ʻO Ganoderma lucidumua kaulana no kona mau waiwai antiviral.I ka wā o ka maʻi ahulau, ʻoi aku ka hopohopo o ka poʻe inā pahaʻO Ganoderma lucidumhe hopena anti-novel coronavirus (SARS-Cov-2).

ʻO ka noiʻi ʻana e nā loea mai Academia Sinica, Taiwan i paʻi ʻia ma ka "Proceedings of the National Academy of Sciences" I ka makahiki 2021 i hōʻike ʻia.ʻO Ganoderma lucidumʻO ka polysaccharide (RF3) loaʻa nā hopena anti-novel coronavirus i loko o nā hoʻokolohua antiviral in vivo a me in vitro, a ʻaʻohe mea ʻawaʻawa.

Ua hōʻike ʻia nā haʻawina he hopena antiviral koʻikoʻi ka RF3 (2 μg/ml) i ka SARS-Cov-2 moʻomeheu in vitro, a loaʻa mau ka hana inhibitory i ka wā i hoʻoheheʻe ʻia i 1280 mau manawa, akā ʻaʻohe ona mea ʻona i ka virus-host Vero E6. pūnaewele.Hooponopono waha oʻO Ganoderma lucidumʻO ka polysaccharide RF3 (ma ka nui o kēlā me kēia lā o 30 mg / kg) hiki ke hōʻemi nui i ka ukana viral (maʻiʻo) i loko o nā māmā o nā hamsters i loaʻa i ka maʻi SARS-Cov-2, akā ʻaʻole i emi ke kaumaha o nā holoholona hoʻokolohua, e hōʻike ana i kēlā.ʻO Ganoderma lucidumʻAʻole ʻona ka polysaccharide (e like me ka mea i hōʻike ʻia ma ke kiʻi ma lalo) [1].

ʻO ka hopena anti-novel coronavirus o ka mea i ʻōlelo ʻia ma lunaʻO Ganoderma lucidumHāʻawi ka polysaccharides i loko o vivo a me in vitro i kumu kumu no ka "hoʻopau ʻana i nā kumu pathogenic" no ka pale ʻana i ka maʻi coronavirus hou.

Nā hopena hoʻokolohua oʻO Ganoderma lucidumpolysaccharides e kūʻē i ka coronavirus novel ma vivo a in vitro

ʻO Ganoderma lucidumhoʻonui i ka hopena o ka maʻi virus.

ʻO nā lāʻau lapaʻau maʻi he hoʻomākaukau autoimmune i hana ʻia e ka attenuating artificially, inactivation a i ʻole genetically modifying virus a i ʻole nā ​​​​mea āpau e pale ai i nā maʻi maʻi.

Mālama ka lāʻau lapaʻau i nā ʻano o ka maʻi maʻi a i ʻole kona mau ʻāpana e hoʻoulu i ka ʻōnaehana pale o ke kino.Hiki ke hoʻomaʻamaʻa i ka ʻōnaehana pale e ʻike i nā maʻi a hoʻoulu i nā immunoglobulins (e like me IgG a me IgA antibodies) e pale aku i nā maʻi bacteria a me nā maʻi viral.Ke komo nā maʻi maʻi i ke kino i ka wā e hiki mai ana, hiki i nā lāʻau lapaʻau ke ʻike a pepehi i nā maʻi maʻi.Hiki nō hoʻi i nā lāʻau lapaʻau ke hoʻoulu i ka pale ʻana o ka cellular a hana i ka hoʻomanaʻo ʻana i ka pale ʻana.Ke komo nā maʻi maʻi i ke kino i ka wā e hiki mai ana, hiki i nā lāʻau lapaʻau ke ʻike a hoʻopau koke i nā maʻi.

Hiki ke ʻike ʻia mai kēia ʻo ke kumu o ka hoʻomaʻamaʻa ʻana ʻo ia hoʻi ka pale ʻana i ka hoʻouka ʻana o nā kumu pathogenic e ka lawa o ka qi olakino i loko o ke kino i loaʻa ai ka palekana antiviral kūikawā.ʻO Ganoderma lucidumHiki i ka polysaccharide wale nō ke hoʻonui i ka pale kino ʻole o ke kino a me ka pale humoral kikoʻī a me ka pale cellular.ʻO ka hui ʻana oʻO Ganoderma luciduma ʻo ka lāʻau lapaʻau (antigen) ka hana o ka adjuvant, hiki ke hoʻonui i ka immunogenicity o antigen a hoʻonui i ka hopena o ka maʻi virus.

Ma ka 'atikala "Adjuvant waiwai oʻO Ganoderma lucidumpolysaccharides - hoʻonui i ka hopena o nā maʻi maʻi maʻi "ma ka helu 92nd oGanodermai 2021, ua hoʻolauna au i ka kikoʻī i kēlāʻO Ganoderma lucidumpolysaccharides i unuhi ʻia a hoʻomaʻemaʻe ʻia maiʻO Ganoderma lucidumHiki i nā kino hua ke hoʻoikaika i nā hopena o nā lāʻau lapaʻau porcine circovirus, nā maʻi maʻi puaʻa puaʻa a me nā moa Newcastle maʻi maʻi virus vaccines, e hoʻoikaika i ka hana o nā antibodies kūikawā a me nā cytokine immune e like me interferon-γ, e hoʻohaʻahaʻa i nā hōʻailona ma muli o ka hoʻouka kauaʻana i nā holoholona hoʻokolohua a ho'ēmi i ka make.Hāʻawi kēia mau haʻawina i kumu no ka noiʻi a me ka hoʻohana ʻana oʻO Ganoderma lucidume hoʻonui i ka hopena o ke kano coronavirus hou.

“ʻO Ganoderma lucidum+ vaccine" hiki ke hoʻomaikaʻi i ka pale. 

He haʻahaʻa haʻahaʻa ka maʻi maʻi ʻo Omicron a he haʻahaʻa ka nui o ka make, akā he maʻi lele.Ma hope o ka hoʻokiʻekiʻe ʻia ʻana o ka mana maʻi maʻi coronavirus hou, nui nā ʻohana a i ʻole nā ​​​​hui i hoʻāʻo maikaʻi ʻia no ka nucleic acid a i ʻole antigen rapid screening.

No laila, ʻo ka mea nui e pale ai i ka poʻe i huli ʻole i ka maikaʻi ʻo ia ka "hoʻoikaika i ka qi olakino a hoʻopau i ka pathogen", ʻo ia hoʻi ka hoʻonui ʻana i ka palekana e pale aku i ka maʻi viral.ʻO Ganoderma lucidumʻo ia kekahi o nā koho maikaʻi loa no ka hoʻonui ʻana i ka palekana.MeGanodermaka pale i hui pū ʻia me ka lāʻau lapaʻau, loaʻa paha iā ʻoe ka manawa e pakele ai.

ʻO ka hope, manaʻolana wau i kēlāʻO Ganoderma lucidumka mea e hoʻoikaika ai i ka qi olakino a hoʻopau i nā pathogens hiki ke hoʻohana ʻia e pale a kāohi i ka maʻi maʻi, lanakila i nā pathogens, a pale i nā mea ola a pau.

Nānā: 1. Jia-Tsrong Jan, et al.ʻO ka ʻike ʻana i nā lāʻau lapaʻau a me nā lāʻau lapaʻau e like me nā mea pale o ka maʻi SARS-CoV-2.Proc Natl Acad Sci USA.2021;118(5): e2021579118.doi: 10.1073/ pnas.2021579118.

PōkoleHoʻolauna ʻo Polofesa Zhi-binLin

Ua hāʻawi ʻo ia iā ia iho i ke aʻo ʻana oGanodermano kahi kokoke i ka hapalua haneli a he paionia ma ke aʻo ʻana o Ganoderma ma Kina.

Ua lawelawe ʻo ia ma ke ʻano he hope pelekikena o ke Kulanui Lapaʻau ʻo Beijing, ka hope dean o ke kula o ka lāʻau lapaʻau kumu o ke Kulanui Lapaʻau ʻo Beijing, ka luna hoʻomalu o ka Institute of Basic Medicine a me ka luna o ke Keʻena ʻOihana Pharmacology o Beijing Medical University.He polopeka 'o ia i ka 'Oihana o Pharmacology, ke Kula o ka Lapaau Kumu o ke Kulanui Lapaau o Beijing.

Mai ka makahiki 1983 a hiki i ka makahiki 1984, he haumana kipa ʻo ia ma ka WHO Traditional Medicine Research Center ma ke Kulanui o Illinois ma Chicago, USA, a he kaukaʻi kipa ma ke Kulanui o Hong Kong mai 2000 a i 2002. Mai ka makahiki 2006, he hanohano ʻo ia. polopeka ma ka Perm State Pharmaceutical Academy ma Rusia.

Mai ka makahiki 1970, ua hoʻohana ʻo ia i nā ʻano sci-tech hou e aʻo ai i nā hopena pharmacological a me nā hana oGanodermaa me kāna mau mea hana a ua hoʻopuka ʻoi aku ma mua o 100 mau pepa noiʻi ma Ganoderma.

Ma 2014 a me 2019, ua hoʻokomo ʻia ʻo ia i ka papa inoa ʻo Most Cited Chinese Researchers i paʻi ʻia e Elsevier no ʻeono mau makahiki.

ʻO ia ka mea kākau o kekahi mauGanodermanā hana e like me "Modern Research on Ganoderma" (1-4 editions), "Lingzhi From Mystery to Science" (1-3 editions), "Adjuvant Treatment of Tumors with Lingzhi e hoʻoikaika i ka qi olakino a hoʻopau i nā pathogens", "E kamaʻilio e pili ana iā Ganoderma ” a me “Ganoderma a me ke Ola”.